This article is more than 5 years old. Information may no longer be current.
Leukemia & Lymphoma Society appoints board members, names chief operating officer
Click Here to Manage Email Alerts
The Leukemia & Lymphoma Society appointed five new members to its board of directors and also named its new chief operating officer.
The board members are Casey Cunningham, MD, chief scientific officer at Santé Ventures, a venture capital fund focused on creating and investing in companies in health care and life sciences; Christopher Flowers, MD, professor in the department of hematology and medical oncology at Emory University School of Medicine; Janice L. Gabrilove, MD, James F. Holland professor of medicine, associate director for education and training at Tisch Cancer Institute and director of the clinical research education program at Icahn School of Medicine at Mount Sinai and the Graduate School of Biomedical Sciences; Ruben A. Mesa, MD, a HemOnc Today Editorial Board member and director of Mays Cancer Center, the newly named home to UT Health San Antonio MD Anderson Cancer Center; and John Greene, senior vice president of Customer Centric Engineering and Site Reliability Engineering at Salesforce.com Inc.
Jorge Benitez, retired chief executive for North America at Accenture, has been named board chairman. He has served on the board since 2010.
.jpg)
Rob Beck has been named the society’s chief operating officer. He joins the society from Citibank, where he most recently served as chief operating officer of the U.S. Retail Bank.
“The Leukemia & Lymphoma Society is at the forefront of cancer cures, and ... I’m pleased to announce significant new board and staff leadership appointments to help us accelerate our mission,” Louis J. DeGennaro, PhD, the society’s president and CEO, said in a press release. “Our new board members bring world-class scientific and medical strength and business acumen, along with their passion and commitment to helping patients. With the addition to our leadership team of Rob Beck as chief operating officer, I’m confident that [the society] is well positioned to maintain growth in our pursuit of a world without blood cancer.”